We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$64.3M
Cap. Flow %
1.08%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Financials 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
76
Verrica Pharmaceuticals
VRCA
$91.9M
$16.2M 0.27%
147,973
– –
SPY icon
77
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$15.8M 0.27%
+50,000
New +$15.3M
SRRA
78
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$14.5M 0.24%
+1,477,320
New +$19.4M
CRVS icon
79
Corvus Pharmaceuticals
CRVS
$1.11B
$14.3M 0.24%
6,767,584
– –
SYRE icon
80
Spyre Therapeutics
SYRE
$8.48B
$13.4M 0.22%
114,621
– –
ZLAB icon
81
Zai Lab
ZLAB
$2.05B
$13.1M 0.22%
254,000
-260,000
-51% -$13.6M
PFNX
82
DELISTED
Pfenex Inc.
PFNX
$11.5M 0.19%
1,305,034
+690,166
+112% +$7.58M
XFOR icon
83
X4 Pharmaceuticals
XFOR
$375M
$10.9M 0.18%
36,216
– –
ALPN
84
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.6M 0.18%
3,670,955
– –
NGNE icon
85
Neurogene
NGNE
$653M
$10.5M 0.18%
46,090
+1,090
+2% +$224K
TECX
86
Tectonic Therapeutic
TECX
$553M
$10.3M 0.17%
55,265
+2,373
+4% +$559K
XLV icon
87
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
$10M 0.17%
113,200
– –
XBI icon
88
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$9.85M 0.17%
127,200
– –
AGIO icon
89
CALL
Agios Pharmaceuticals
AGIO
$2.09B
$8.87M 0.15%
+250,000
New +$11.6M
CTIC
90
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$8.76M 0.15%
9,520,600
+4,520,600
+90% +$5.18M
RGNX icon
91
Regenxbio
RGNX
$613M
$8.67M 0.15%
267,700
+240,900
+899% +$10M
REGN icon
92
Regeneron Pharmaceuticals
REGN
$73.2B
$8.4M 0.14%
17,200
-192,100
-92% -$79.2M
MRSN
93
DELISTED
Mersana Therapeutics
MRSN
$7.85M 0.13%
53,869
-29,064
-35% -$5.08M
TVRD
94
Tvardi Therapeutics
TVRD
$23.1M
$7.83M 0.13%
+16,467
New +$8.95M
ADAP
95
DELISTED
Adaptimmune Therapeutics
ADAP
$6.87M 0.12%
2,525,654
+1,174,999
+87% +$3.9M
RVMD icon
96
Revolution Medicines
RVMD
$38.6B
$6.57M 0.11%
+300,000
New +$8.3M
HRTX icon
97
Heron Therapeutics
HRTX
$93.2M
$6.31M 0.11%
+537,420
New +$10.1M
OBSV
98
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.28M 0.11%
2,605,531
– –
RNAC icon
99
Cartesian Therapeutics
RNAC
$224M
$6.25M 0.11%
86,462
-9,507
-10% -$918K
XTNT icon
100
Xtant Medical Holdings
XTNT
$57.7M
$6.17M 0.1%
9,207,012
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.